{
  "id": 3986790,
  "title": "Biontech: Biontech bricht Studie zu Impfstoff für Darmkrebstherapie ab – Aktie verliert zehn Prozent",
  "url": "https://urgent.news/2026/08/28/biontech-biontech-bricht-studie-zu-impfstoff-fur-darmkrebstherapie-ab",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-28T15:07:33.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/unternehmen/industrie/biontech-pharmaunternehmen-bricht-studie-ab-aktie-verliert-zehn-prozent/100250446.html"
  },
  "original_language": "de",
  "account": "Berlin - The biotech company BioNTech has halted a Phase-II trial for an mRNA vaccine designed to treat colorectal cancer. The therapy, known as Autogene Cevumeran, was tested on autologous vaccine patients who have already undergone surgery. An independent Data Safety Monitoring Board had previously noted that the data was insufficient to make reliable claims about the vaccine's effectiveness. The board concluded that continuing the study would not likely change the efficacy signal. BioNTech announced the suspension on Friday, and the stock price fell by up to ten percent on the New York Stock Exchange. BioNTech co-founder Özlem Türeci stated that while the result was not what they had hoped for, it provided important scientific insights for further development. The drug was developed by BioNTech in collaboration with Roche's Genentech subsidiary for patients in high-risk stages II or III, whose tumors had already been surgically removed. Another Phase-2 study using the same drug to treat pancreatic cancer was not affected by the stop and will proceed as planned. BioNTech had gained widespread attention in the public eye during the COVID-19 pandemic due to its coronavirus vaccine. Following the pandemic, the company's management returned its strategic focus to oncology.",
  "summary": "Erst Mitte August hatte das Unternehmen noch für Aufsehen gesorgt – bei einem anderen Studienerfolg. Damals hatten die Papiere mehr als 100 Prozent zugelegt. Nun verkaufen Anleger wieder.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}